Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 4:45 pm Sale | 2022-12-31 | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | RA Capital Management, L.P. | 0 0.000% | -2,850,000 (Position Closed) | Filing History |
| 2023-02-14 3:01 pm Sale | 2022-12-31 | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | Rock Springs Capital Management LP | 0 0.000% | -2,581,299 (Position Closed) | Filing History |
| 2023-02-14 2:26 pm Sale | 2022-12-31 | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | Avidity Partners Management LP | 2,040,000 4.100% | -2,365,000 (-53.69%) | Filing History |
| 2023-02-06 3:02 pm Sale | 2022-12-30 | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | Wellington Management Group LLP | 0 0.000% | -2,869,650 (Position Closed) | Filing History |
| 2022-11-04 4:42 pm Sale | 2022-11-03 | 13D | PHASEBIO PHARMACEUTICALS INC C PHASQ | New Enterprise Associates 13, L.P. | 0 0.000% | -6,641,634 (Position Closed) | Filing History |
| 2022-07-19 11:30 am Purchase | 2022-07-12 | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | MAI Capital Management | 2,675,376 5.800% | 2,675,376 (New Position) | Filing History |
| 2022-02-14 6:24 pm Purchase | 2021-12-31 | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | Rock Springs Capital Management LP | 2,581,299 5.370% | 1,266,925 (+96.39%) | Filing History |
| 2022-02-14 4:12 pm Sale | 2021-12-31 | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | Rosalind Advisors, Inc. | 707,467 1.500% | -1,900,390 (-72.87%) | Filing History |
| 2022-02-14 4:11 pm Unchanged | 2021-12-31 | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | RA Capital Management, L.P. | 2,850,000 5.900% | 0 (Unchanged) | Filing History |
| 2022-02-11 7:52 pm Purchase | 2021-12-31 | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | Avidity Partners Management LP | 4,405,000 9.200% | 120,000 (+2.80%) | Filing History |
| 2022-02-04 09:29 am Purchase | 2021-12-31 | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | Wellington Management Group LLP | 2,869,650 5.970% | 944,570 (+49.07%) | Filing History |
| 2022-02-01 2:42 pm Unchanged | 2021-12-31 | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | JOHNSON & JOHNSON JNJ | 1,607,044 3.300% | 0 (Unchanged) | Filing History |
| 2021-11-10 08:51 am Sale | 2021-10-29 | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | Wellington Management Group LLP | 1,925,080 4.010% | -4,089,809 (-67.99%) | Filing History |